{"component": "contracts", "props": {"contracts": [{"intro": "This SECURITY AGREEMENT, dated as of June 26, 2013 (this \u201cAgreement\u201d), is among Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), each Subsidiary of the Company that becomes a party to this Agreement by execution and delivery of the form annexed hereto as Annex A and the Subsidiary Guaranty annexed thereto (each such Subsidiary, the \u201cGuarantor\u201d and together with the Company, the \u201cDebtors\u201d), Collateral Agents, LLC, as collateral agent (the \u201cCollateral Agent\u201d) for and the holders of the Company\u2019s Secured Convertible Notes due December 26, 2013 which were issued on June 26, 2013, in the original aggregate principal amount of up to $7,000,000 (collectively, the \u201cNotes\u201d) (collectively, the \u201cSecured Parties\u201d).", "id": "hjHcC8OuBO6", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713113002429/ex10-4.htm", "category_name": "Security Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 2nd, 2013", "published": true, "pretty": null, "uri": "/contracts/hjHcC8OuBO6", "title": "SECURITY AGREEMENT", "group_id": "asIVG02NVjc", "group_samples": [{"label": "Security Agreement (Vitro Biopharma, Inc.)", "uri": "/contracts/eg76OUc0lSw", "published": true}, {"label": "Security Agreement (Biofrontera Inc.)", "uri": "/contracts/kE9P1bsOcAo", "published": true}, {"label": "Security Agreement (Wearable Health Solutions, Inc.)", "uri": "/contracts/e7GC9gzVXEU", "published": true}], "group_size": 11, "tags": [{"name": "Security Agreement", "type": "category", "uri": "/contracts/tagged/security-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This letter (the \u201cAgreement\u201d) constitutes the agreement between Maxim Group LLC (\u201cMaxim\u201d or the \u201cPlacement Agent\u201d) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the \u201cPlacement\u201d) of an aggregate of 3,573,255 shares of (the \u201cShares\u201d) of the Company\u2019s common stock, par value $0.0001 per share (\u201cCommon Stock\u201d) and warrants to purchase up to 3,573,255 of the shares of Common Stock (each a \u201cWarrant\u201d and collectively, the \u201cWarrants\u201d). The Shares, the Warrants and the shares of Common Stock underlying the Warrants (the \u201cWarrant Shares\u201d) are hereinafter referred to collectively as the \u201cSecurities.\u201d The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a \u201cPurchaser\u201d and collectively, the \u201cPurchasers\u201d) and nothing herein constitutes that Maxim would have the power or autho", "id": "beLJWFsn9fd", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713116006230/ex10-1.htm", "category_name": "Placement Agent Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 29th, 2016", "published": true, "pretty": null, "uri": "/contracts/beLJWFsn9fd", "title": "ADAMIS PHARMACEUTICALS CORPORATION 8-K", "group_id": "43OrIburuRU", "group_samples": [{"label": "Placement Agent Agreement (Interpace Diagnostics Group, Inc.)", "uri": "/contracts/ju8bUyCOmAn", "published": true}, {"label": "Placement Agent Agreement (Interpace Diagnostics Group, Inc.)", "uri": "/contracts/glQcQFSWVcr", "published": true}, {"label": "Placement Agent Agreement (Interpace Diagnostics Group, Inc.)", "uri": "/contracts/hqpuTvFTuIx", "published": true}], "group_size": 9, "tags": [{"name": "Placement Agent Agreement", "type": "category", "uri": "/contracts/tagged/placement-agent-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "2UMMs2Z7Ytw", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000095000597000777/1.txt", "category_name": "Common Stock Purchase Agreement", "company_name": "Cellegy Pharmaceuticals Inc", "created": "September 19th, 1997", "published": true, "pretty": null, "uri": "/contracts/2UMMs2Z7Ytw", "title": "EXHIBIT 4.4 CELLEGY PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (this \"Agreement\") is made and entered into as of July 23, 1997 by and among Cellegy Pharmaceuticals, Inc., a California corporation (the...", "group_id": "70oL05STRjP", "group_samples": [{"label": "Common Stock Purchase Agreement (Eurotech LTD)", "uri": "/contracts/ecFXpE4E8vC", "published": true}, {"label": "Common Stock Purchase Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/2UMMs2Z7Ytw", "published": true}, {"label": "Common Stock Purchase Agreement (Cepheid)", "uri": "/contracts/7ULVbCoxYwI", "published": true}], "group_size": 7, "tags": [{"name": "Common Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/common-stock-purchase-agreement"}, {"name": "Cellegy Pharmaceuticals Inc", "type": "company", "uri": "/company/887247/cellegy-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "THIS EXECUTIVE EMPLOYMENT AGREEMENT (this \u201cAgreement\u201d) is dated as of October 23, 2023 (the \u201cEffective Date\u201d) and is entered into by and between DMK Pharmaceuticals Inc., a Delaware corporation (the \u201cCompany\u201d), and John Dorbin (\u201cExecutive\u201d).", "id": "cHBXXTXDuUN", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000199937123000197/ex10-7.htm", "category_name": "Executive Employment Agreement", "company_name": "DMK PHARMACEUTICALS Corp", "created": "November 14th, 2023", "published": true, "pretty": null, "uri": "/contracts/cHBXXTXDuUN", "title": "EXECUTIVE EMPLOYMENT AGREEMENT", "group_id": "6IakyEWIOaI", "group_samples": [{"label": "Executive Employment Agreement (DMK PHARMACEUTICALS Corp)", "uri": "/contracts/cHBXXTXDuUN", "published": true}, {"label": "Executive Employment Agreement (DMK PHARMACEUTICALS Corp)", "uri": "/contracts/6IakyEWIOaI", "published": true}, {"label": "Executive Employment Agreement (DMK PHARMACEUTICALS Corp)", "uri": "/contracts/jLTd4uLwlOA", "published": true}], "group_size": 6, "tags": [{"name": "Executive Employment Agreement", "type": "category", "uri": "/contracts/tagged/executive-employment-agreement"}, {"name": "DMK PHARMACEUTICALS Corp", "type": "company", "uri": "/company/887247/dmk-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "THIS COMMON STOCK PURCHASE WARRANT (the \u201cWarrant\u201d) certifies that, for value received, Lincoln Park Capital Fund, LLC or its assigns (the \u201cHolder\u201d) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January 3, 2023 (the \u201cInitial Exercise Date\u201d) and on or prior to 5:00 p.m. (New York City time) on January 5, 2028 (the \u201cTermination Date\u201d) but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), up to 750,000 shares (as subject to adjustment hereunder, the \u201cWarrant Shares\u201d) of Common Stock. The purchase price of one share of the Company\u2019s Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).", "id": "cshhtOGh6R", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713122007476/ex4-1.htm", "category_name": "Security Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 6th, 2022", "published": true, "pretty": null, "uri": "/contracts/cshhtOGh6R", "title": "COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION", "group_id": "axTnWDNDzBw", "group_samples": [{"label": "Security Agreement (60 Degrees Pharmaceuticals, Inc.)", "uri": "/contracts/axTnWDNDzBw", "published": true}, {"label": "Security Agreement (60 Degrees Pharmaceuticals, Inc.)", "uri": "/contracts/1RurS3jdi2J", "published": true}, {"label": "Security Agreement (Liquid Media Group Ltd.)", "uri": "/contracts/4cvxPBey1wi", "published": true}], "group_size": 6, "tags": [{"name": "Security Agreement", "type": "category", "uri": "/contracts/tagged/security-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This letter (the \u201cAgreement\u201d) constitutes the agreement between Maxim Group LLC (the \u201cPlacement Agent\u201d) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a \u201creasonable best efforts\u201d basis, in connection with the proposed placement (the \u201cPlacement\u201d) to certain purchasers (the \u201cPurchasers\u201d) of up to an aggregate of (i) 4,800,000 common units (each a \u201cCommon Unit\u201d and collectively, the \u201cCommon Units\u201d), with each Common Unit consisting of (A) one share (each a \u201cShare\u201d and collectively, the \u201cShares\u201d) of the Company\u2019s common stock, par value $0.0001 per share (the \u201cCommon Stock\u201d), (B) one common stock purchase warrant (each a \u201cWarrant\u201d and collectively, the \u201cWarrants\u201d) to purchase one share of Common Stock (the \u201cWarrant Shares\u201d) exercisable immediately and expiring five years after the date of issuance at an exercise price of $1.35 per share of Common Stock, and (ii) 1,130,", "id": "as98Qk92EjA", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713123009282/ex1-1.htm", "category_name": "Placement Agent Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "August 3rd, 2023", "published": true, "pretty": null, "uri": "/contracts/as98Qk92EjA", "title": "Adamis Pharmaceuticals Corporation 8-K", "group_id": "10Dk6QtSLQ9", "group_samples": [{"label": "Placement Agent Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/as98Qk92EjA", "published": true}, {"label": "Placement Agent Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/lWtT6YpyMXv", "published": true}, {"label": "Placement Agent Agreement (Agrify Corp)", "uri": "/contracts/flOjZK48d98", "published": true}], "group_size": 5, "tags": [{"name": "Placement Agent Agreement", "type": "category", "uri": "/contracts/tagged/placement-agent-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This letter (the \u201cAgreement\u201d) constitutes the agreement between Adamis Pharmaceuticals Corporation (the \u201cCompany\u201d) and Maxim Group, LLC (\u201cMaxim\u201d or the \u201cLead Manager\u201d), that Maxim shall serve as the exclusive lead placement agent for the Company, on a \u201creasonable best efforts\u201d basis ( a \u201cPlacement\u201d), in connection with the proposed offerings of shares (the \u201cShares\u201d) or the \u201cSecurities\u201d) of the Company\u2019s common stock, par value $0.0001 per share (the \u201cCommon Stock\u201d) and warrants to purchase shares of Common Stock (the \u201cWarrants\u201d and, together with the Shares, the \u201cSecurities\u201d). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the Lead Manager and, if a Direct Placement, the purchasers (each, a \u201cPurchaser\u201d and collectively, the \u201cPurchasers\u201d) and nothing herein grants Maxim the power or authority to bind the Company or any Purchaser or creates an obligation for the Company to issue any Securities or complete the Placement. This Agreement and ", "id": "iyEwkCZTcYc", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713120002070/ex10-2.htm", "category_name": "Placement Agent Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "February 21st, 2020", "published": true, "pretty": null, "uri": "/contracts/iyEwkCZTcYc", "title": "Adamis Pharmaceuticals Corporation 8-K", "group_id": "c9IoglffKXr", "group_samples": [{"label": "Placement Agent Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/iyEwkCZTcYc", "published": true}, {"label": "Placement Agent Agreement (Sintx Technologies, Inc.)", "uri": "/contracts/jf03znQSSCp", "published": true}, {"label": "Placement Agent Agreement (Sintx Technologies, Inc.)", "uri": "/contracts/jhiE7ceDWnz", "published": true}], "group_size": 5, "tags": [{"name": "Placement Agent Agreement", "type": "category", "uri": "/contracts/tagged/placement-agent-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "SUBSIDIARY GUARANTEE, dated as of June ___, 2012 (this \u201cGuarantee\u201d), made by Adamis Corporation, a Delaware corporation, Adamis Laboratories, Inc., a Delaware corporation, and Adamis Viral Therapies, Inc., a Delaware corporation (collectively and together with any other entity that may become a party hereto as provided herein, the \u201cGuarantor\u201d, and together with the Company (as defined below), the \u201cDebtors\u201d), in favor of the purchaser (including such purchaser\u2019s successors, transferees and assigns, the \u201cPurchaser\u201d) signatory to the Purchase Agreement (as defined below).", "id": "24j3EtWJf8U", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713112001919/ex10_3.htm", "category_name": "Subsidiary Guarantee", "company_name": "Adamis Pharmaceuticals Corp", "created": "June 15th, 2012", "published": true, "pretty": null, "uri": "/contracts/24j3EtWJf8U", "title": "SUBSIDIARY GUARANTEE", "group_id": "24j3EtWJf8U", "group_samples": [{"label": "Subsidiary Guarantee (Adamis Pharmaceuticals Corp)", "uri": "/contracts/24j3EtWJf8U", "published": true}, {"label": "Subsidiary Guarantee (Adamis Pharmaceuticals Corp)", "uri": "/contracts/lvlE2jfNLla", "published": true}, {"label": "Subsidiary Guarantee (IdeaEdge, Inc)", "uri": "/contracts/gys9vrylGra", "published": true}], "group_size": 4, "tags": [{"name": "Subsidiary Guarantee", "type": "category", "uri": "/contracts/tagged/subsidiary-guarantee"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS STOCK REPURCHASE AGREEMENT (this \u201cAgreement\u201d) is made as of the 3rd day of November 2008 by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), and Robert Hopkins (\u201cStockholder\u201d).", "id": "9ZM539iGgAH", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000114420409001593/v136226_ex10-35.htm", "category_name": "Stock Repurchase Agreement", "company_name": "Cellegy Pharmaceuticals Inc", "created": "January 12th, 2009", "published": true, "pretty": null, "uri": "/contracts/9ZM539iGgAH", "title": "Adamis Pharmaceuticals Corporation STOCK REPURCHASE AGREEMENT", "group_id": "9ZM539iGgAH", "group_samples": [{"label": "Stock Repurchase Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/a97boRJcWXN", "published": true}, {"label": "Stock Repurchase Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/atglq4iOcDf", "published": true}, {"label": "Stock Repurchase Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/9ZM539iGgAH", "published": true}], "group_size": 4, "tags": [{"name": "Stock Repurchase Agreement", "type": "category", "uri": "/contracts/tagged/stock-repurchase-agreement"}, {"name": "Cellegy Pharmaceuticals Inc", "type": "company", "uri": "/company/887247/cellegy-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Standard Form Modified Gross Office Lease (\u201cLease\u201d) is entered into effective as of April 1, 2014, between PACIFIC NORTH COURT HOLDINGS, L.P., a California limited partnership (\u201cLandlord\u201d), and ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (\u201cTenant\u201d), who agree as follows:", "id": "jhHKvUekAKm", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000156459015002012/admp-ex1050_20141231306.htm", "category_name": "Office Lease Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "March 26th, 2015", "published": true, "pretty": null, "uri": "/contracts/jhHKvUekAKm", "title": "OFFICE LEASE AGREEMENT BETWEEN PACIFIC NORTH COURT HOLDINGS, L.P., AS LANDLORD AND", "group_id": "bsgwvM9dUFq", "group_samples": [{"label": "Office Lease Agreement (IDEAYA Biosciences, Inc.)", "uri": "/contracts/5APx1XXsU7M", "published": true}, {"label": "Office Lease Agreement (Evoke Pharma Inc)", "uri": "/contracts/23mWcOfBu2n", "published": true}, {"label": "Office Lease Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/jhHKvUekAKm", "published": true}], "group_size": 4, "tags": [{"name": "Office Lease Agreement", "type": "category", "uri": "/contracts/tagged/office-lease-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "THIS SUPPORT AGREEMENT (this \u201cSupport Agreement\u201d) is made and entered into as of February 24, 2023, by and between (i) each of the undersigned identified on the signature page hereof as a \u201cSecurityholder\u201d (each, a \u201cSecurityholder\u201d); (ii) DMK Pharmaceuticals Corporation, a New Jersey corporation (\u201cDMK\u201d); (iii) Adamis Pharmaceuticals Corporation, a Delaware corporation (\u201cAPC\u201d); and (iv) Aardvark Merger Sub, Inc., a Delaware corporation (\u201cMerger Sub,\u201d and together with APC, \u201cAdamis\u201d).", "id": "kFy4d1WhxnC", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713123006540/ex10-2.htm", "category_name": "Support Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "May 15th, 2023", "published": true, "pretty": null, "uri": "/contracts/kFy4d1WhxnC", "title": "SUPPORT AGREEMENT", "group_id": "6JUy5PCnF1r", "group_samples": [{"label": "Support Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/kFy4d1WhxnC", "published": true}, {"label": "Support Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/6JUy5PCnF1r", "published": true}, {"label": "Support Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/dqe6mSVBWGD", "published": true}], "group_size": 3, "tags": [{"name": "Support Agreement", "type": "category", "uri": "/contracts/tagged/support-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Agreement is made effective the 26th day of January, 2007, by and between Wisconsin Alumni Research Foundation (hereinafter called \"WARF\"), a nonstock, nonprofit Wisconsin corporation, and Colby Pharmaceutical Company (hereinafter called \"Licensee\"), a corporation organized and existing under the laws of Delaware;", "id": "99myDXez4CW", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713111001205/ex-10_44.htm", "category_name": "Standard Exclusive Start-Up Company License Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 7th, 2011", "published": true, "pretty": null, "uri": "/contracts/99myDXez4CW", "title": "STANDARD EXCLUSIVE START-UP COMPANY LICENSE AGREEMENT", "group_id": "99myDXez4CW", "group_samples": [{"label": "Standard Exclusive Start Up Company License Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/99myDXez4CW", "published": true}, {"label": "Standard Exclusive Start Up Company License Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/9AMThOk2Qbd", "published": true}, {"label": "Standard Exclusive Start Up Company License Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/icqYGXxqDyy", "published": true}], "group_size": 3, "tags": [{"name": "Standard Exclusive Start-Up Company License Agreement", "type": "category", "uri": "/contracts/tagged/standard-exclusive-start-up-company-license-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS NOTE is a duly authorized and validly issued 10% Senior Convertible Note of ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (the \u201cCompany\u201d), having its principal place of business at 11455 El Camino Real, Suite 310, San Diego, CA 92130 (this \u201cNote\u201d).", "id": "emN5t1dssnN", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713112001919/ex10_2.htm", "category_name": "Convertible Security Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "June 15th, 2012", "published": true, "pretty": null, "uri": "/contracts/emN5t1dssnN", "title": "ADAMIS PHARMACEUTICALS CORPORATION 10% SENIOR CONVERTIBLE NOTE", "group_id": "hdksBSBPNQq", "group_samples": [{"label": "Convertible Security Agreement (AtheroNova Inc.)", "uri": "/contracts/hdksBSBPNQq", "published": true}, {"label": "Convertible Security Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/emN5t1dssnN", "published": true}, {"label": "Convertible Security Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/4v5loxhMUbg", "published": true}], "group_size": 3, "tags": [{"name": "Convertible Security Agreement", "type": "category", "uri": "/contracts/tagged/convertible-security-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS COMMON STOCK PURCHASE WARRANT (the \u201cWarrant\u201d) certifies that, for value received, Lincoln Park Capital Fund, LLC or its assigns (the \u201cHolder\u201d) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January 3, 2023 (the \u201cInitial Exercise Date\u201d) and on or prior to 5:00 p.m. (New York City time) on January 5, 2028 (the \u201cTermination Date\u201d) but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), up to 750,000 shares (as subject to adjustment hereunder, the \u201cWarrant Shares\u201d) of Common Stock. The purchase price of one share of the Company\u2019s Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).", "id": "bclP5bIgxsP", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713122007475/ex4-1.htm", "category_name": "Securities Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 6th, 2022", "published": true, "pretty": null, "uri": "/contracts/bclP5bIgxsP", "title": "COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION", "group_id": "j5BTbObsPCS", "group_samples": [{"label": "Securities Agreement (T2 Biosystems, Inc.)", "uri": "/contracts/kOo1JbigrTz", "published": true}, {"label": "Securities Agreement (MGT Capital Investments, Inc.)", "uri": "/contracts/j5BTbObsPCS", "published": true}, {"label": "Securities Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/bclP5bIgxsP", "published": true}], "group_size": 3, "tags": [{"name": "Securities Agreement", "type": "category", "uri": "/contracts/tagged/securities-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Securities Purchase Agreement (\u201cAgreement\u201d) is entered into as of June 11, 2012 by and between ADAMIS PHARMACEUTICALS CORPORATION, a corporation organized under the laws of the State of Delaware (the \u201cCompany\u201d), and GEMINI MASTER FUND, LTD., a Cayman Islands corporation (\u201cPurchaser\u201d).", "id": "1mPNGv7BNJm", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713112001919/ex10_1.htm", "category_name": "Securities Purchase Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "June 15th, 2012", "published": true, "pretty": null, "uri": "/contracts/1mPNGv7BNJm", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "1mPNGv7BNJm", "group_samples": [{"label": "Securities Purchase Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/2J3TI0fygvZ", "published": true}, {"label": "Securities Purchase Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/1mPNGv7BNJm", "published": true}], "group_size": 2, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "By means of this letter agreement (the \u201cAgreement\u201d), we are pleased to confirm the terms of your employment, effective as of the Effective Date (as defined below) and subject to the other terms and conditions herein, with Cellegy Pharmaceuticals, Inc. (\u201cCellegy\u201d or the \u201cCompany\u201d).", "id": "616ezL95vQG", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000110465905013943/a05-5589_1ex10d18.htm", "category_name": "Employment Agreement", "company_name": "Cellegy Pharmaceuticals Inc", "created": "March 31st, 2005", "published": true, "pretty": null, "uri": "/contracts/616ezL95vQG", "title": "October 7, 2004", "group_id": "2ACEzAUZwgS", "group_samples": [{"label": "Employment Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/616ezL95vQG", "published": true}, {"label": "Employment Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/2ACEzAUZwgS", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Cellegy Pharmaceuticals Inc", "type": "company", "uri": "/company/887247/cellegy-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Pennsylvania", "type": "jurisdiction", "uri": "/contracts/tagged/pennsylvania-us"}]}, {"intro": "This Registration Rights Agreement (the \u201cAgreement\u201d) is dated as of August 19, 2014 (the \u201cAgreement Date\u201d) and is entered into by and among Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), and the \u201cInvestors\u201d named in that certain Purchase Agreement dated the date hereof and entered into by and between the Company and each of the Investors (the \u201cPurchase Agreement\u201d). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.", "id": "bT2FNzTsQZx", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713114003073/ex10-2.htm", "category_name": "Registration Rights Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "August 20th, 2014", "published": true, "pretty": null, "uri": "/contracts/bT2FNzTsQZx", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "2Yi2PI5pK8g", "group_samples": [{"label": "Registration Rights Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/bT2FNzTsQZx", "published": true}, {"label": "Registration Rights Agreement (Crossroads Systems Inc)", "uri": "/contracts/2Yi2PI5pK8g", "published": true}], "group_size": 2, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Distribution and Commercialization Agreement (the \u201cAgreement\u201d) is made effective as of the Effective Date by and between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of Delaware (the \u201cCompany\u201d), with an office located at 11682 El Camino Real, Suite #300, San Diego, CA 92130 and Sandoz Inc., a corporation organized under the laws of Colorado, with an office at 100 College Road West, Princeton, New Jersey 08540 (\u201cSandoz\u201d). Sandoz and the Company may hereafter be referred to collectively as the \u201cParties\u201d and individually as a \u201cParty\u201d.", "id": "dQJwO6oHp99", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713118006055/ex10-1.htm", "category_name": "Distribution and Commercialization Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "November 9th, 2018", "published": true, "pretty": null, "uri": "/contracts/dQJwO6oHp99", "title": "DISTRIBUTION AND COMMERCIALIZATION AGREEMENT", "group_id": "4MtzJhQbZxM", "group_samples": [{"label": "Distribution and Commercialization Agreement", "uri": "/contracts/4MtzJhQbZxM", "published": true}, {"label": "Distribution and Commercialization Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/dQJwO6oHp99", "published": true}], "group_size": 2, "tags": [{"name": "Distribution and Commercialization Agreement", "type": "category", "uri": "/contracts/tagged/distribution-and-commercialization-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this \u201cAgreement\u201d) is made and entered into on May 9, 2016 (the \u201cEffective Date\u201d), by and between Watson Laboratories, Inc., a Nevada corporation (\u201cWatson\u201d), on the one hand, and Adamis Pharmaceuticals Corporation, a company incorporated under the laws of Delaware (\u201cAdamis\u201d), on the other hand. Watson and Adamis shall each sometimes be referred to herein as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "hoGqBaVTjsM", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713116006612/ex10-6.htm", "category_name": "Development, License and Commercialization Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "August 15th, 2016", "published": true, "pretty": null, "uri": "/contracts/hoGqBaVTjsM", "title": "Designates portions of this document have been omitted pursuant to a request for confidential treatment filed separately with the Commission] DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT", "group_id": "4Oio8e5NGQI", "group_samples": [{"label": "Development, License and Commercialization Agreement", "uri": "/contracts/4Oio8e5NGQI", "published": true}, {"label": "Development, License and Commercialization Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/hoGqBaVTjsM", "published": true}], "group_size": 2, "tags": [{"name": "Development, License and Commercialization Agreement", "type": "category", "uri": "/contracts/tagged/development-license-and-commercialization-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS VOTING AGREEMENT (this \u201cVoting Agreement\u201d) is made and entered into as of February 12, 2008, by and between the undersigned stockholder (the \u201cStockholder\u201d) of Cellegy Pharmaceuticals, Inc., a Delaware corporation (\u201cCellegy\u201d), and Adamis Pharmaceuticals Corporation, a Delaware corporation (\u201cAdamis\u201d).", "id": "K6lG3tB7Gu", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000114420408063047/v131088_ex2-5.htm", "category_name": "Voting Agreement", "company_name": "Cellegy Pharmaceuticals Inc", "created": "November 13th, 2008", "published": true, "pretty": null, "uri": "/contracts/K6lG3tB7Gu", "title": "VOTING AGREEMENT", "group_id": "4ztuXk6oRaG", "group_samples": [{"label": "Voting Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/4ztuXk6oRaG", "published": true}, {"label": "Voting Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/K6lG3tB7Gu", "published": true}], "group_size": 2, "tags": [{"name": "Voting Agreement", "type": "category", "uri": "/contracts/tagged/voting-agreement"}, {"name": "Cellegy Pharmaceuticals Inc", "type": "company", "uri": "/company/887247/cellegy-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS SUBLEASE (\u201cSublease\u201d), dated as of March 12, 2011 is made by and between WHITNEY, BRADLEY & BROWN Inc., a Virginia Corporation Sublandlord\u201d), and _ADAMIS PHARMACEUTICALS, a Delaware Corporation] (\u201cSubtenant\u201d).", "id": "fVyn8q0HygZ", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713113004389/ex10-49.htm", "category_name": "Sublease", "company_name": "Adamis Pharmaceuticals Corp", "created": "November 15th, 2013", "published": true, "pretty": null, "uri": "/contracts/fVyn8q0HygZ", "title": "SUBLEASE", "group_id": "5tA3xLy6TUr", "group_samples": [{"label": "Sublease (Adamis Pharmaceuticals Corp)", "uri": "/contracts/fVyn8q0HygZ", "published": true}, {"label": "Sublease (Adamis Pharmaceuticals Corp)", "uri": "/contracts/5tA3xLy6TUr", "published": true}], "group_size": 2, "tags": [{"name": "Sublease", "type": "category", "uri": "/contracts/tagged/sublease"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amended and Restated Registration Rights Agreement (the \u201cAgreement\u201d) is dated as of January 26, 2016 (the \u201cAgreement Date\u201d) and is entered into by and among Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), and the \u201cInvestors\u201d named in that certain Purchase Agreement dated August 19, 2014 by and between the company and each of the Investors (the \u201c2014 Purchase Agreement\u201d) and that certain Purchase Agreement dated the date hereof and entered into by and between the Company and each of the Investors (the \u201c2016 Purchase Agreement\u201d and collectively with the 2014 Purchase Agreement, \u201cPurchase Agreement\u201d). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement, unless otherwise defined herein.", "id": "dxNmTAo2wJC", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713116003959/ex10-2.htm", "category_name": "Registration Rights Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "January 26th, 2016", "published": true, "pretty": null, "uri": "/contracts/dxNmTAo2wJC", "title": "AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT", "group_id": "6lR5bNyNa76", "group_samples": [{"label": "Registration Rights Agreement (Integrated Surgical Systems Inc)", "uri": "/contracts/6lR5bNyNa76", "published": true}, {"label": "Registration Rights Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/dxNmTAo2wJC", "published": true}], "group_size": 2, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Third Amendment to Common Stock Purchase Agreement (this \u201cThird Amendment\u201d) is dated as of January 31, 2012 (the \u201cEffective Date\u201d), and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d) and Eses Holdings (FZE), a limited liability free zone establishment formed in accordance with the laws of Sharjah, United Arab Emirates (\u201cPurchaser\u201d and together with the Company, the \u201cParties\u201d, and each, individually, a \u201cParty\u201d).", "id": "fOcoukIocVp", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713112000314/ex-10_1.htm", "category_name": "Common Stock Purchase Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "February 14th, 2012", "published": true, "pretty": null, "uri": "/contracts/fOcoukIocVp", "title": "COMMON STOCK PURCHASE AGREEMENT", "group_id": "87nHeVvG2gi", "group_samples": [{"label": "Common Stock Purchase Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/fOcoukIocVp", "published": true}, {"label": "Common Stock Purchase Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/87nHeVvG2gi", "published": true}], "group_size": 2, "tags": [{"name": "Common Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/common-stock-purchase-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "SUBSIDIARY GUARANTEE, dated as of January 11, 2010 (this \u201cGuarantee\u201d), made by Adamis Corporation, a Delaware corporation, Adamis Laboratories, Inc., a Delaware corporation, and Adamis Viral Therapies, Inc., a Delaware corporation (collectively and together with any other entity that may become a party hereto as provided herein, the \u201cGuarantor\u201d, and together with the Company (as defined below), the \u201cDebtors\u201d), in favor of the purchaser(s) (including such purchaser\u2019s(s\u2019) successors, transferees and assigns, the \u201cPurchasers\u201d) signatory to the Purchase Agreement (as defined below).", "id": "aTV36bP3C4u", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713110000053/ex-10_5.htm", "category_name": "Subsidiary Guarantee", "company_name": "Adamis Pharmaceuticals Corp", "created": "January 15th, 2010", "published": true, "pretty": null, "uri": "/contracts/aTV36bP3C4u", "title": "SUBSIDIARY GUARANTEE", "group_id": "aTV36bP3C4u", "group_samples": [{"label": "Subsidiary Guarantee (Adamis Pharmaceuticals Corp)", "uri": "/contracts/aTV36bP3C4u", "published": true}, {"label": "Subsidiary Guarantee (Axis Technologies Group Inc)", "uri": "/contracts/k24XkCPlmxb", "published": true}], "group_size": 2, "tags": [{"name": "Subsidiary Guarantee", "type": "category", "uri": "/contracts/tagged/subsidiary-guarantee"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Share Purchase Agreement (the \u201cAgreement\u201d) is dated as of March 31, 2006, and is entered into by and between Cellegy Pharmaceuticals, Inc., a Delaware corporation with an address of 1800 Byberry Road, Building 13, Huntingdon Valley, PA 19006, United States of America (\u201cCellegy\u201d or \u201cSeller\u201d), and Epsilon Pharmaceuticals Pty Ltd ACN 118 178 699, an Australian company with an address of 203 New South Head Road, Edgecliff, New South Wales 2027, Australia (\u201cPurchaser\u201d).", "id": "dPyEYlmm00x", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000114420406032091/v049342_ex2-1.htm", "category_name": "Share Purchase Agreement", "company_name": "Cellegy Pharmaceuticals Inc", "created": "August 10th, 2006", "published": true, "pretty": null, "uri": "/contracts/dPyEYlmm00x", "title": "SHARE PURCHASE AGREEMENT", "group_id": "dPyEYlmm00x", "group_samples": [{"label": "Share Purchase Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/dPyEYlmm00x", "published": true}, {"label": "Share Purchase Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/jmgEzJq26qy", "published": true}], "group_size": 2, "tags": [{"name": "Share Purchase Agreement", "type": "category", "uri": "/contracts/tagged/share-purchase-agreement"}, {"name": "Cellegy Pharmaceuticals Inc", "type": "company", "uri": "/company/887247/cellegy-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New South Wales", "type": "jurisdiction", "uri": "/contracts/tagged/new-south-wales-au"}]}, {"intro": "", "id": "eAwZU310eLv", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000183988223004983/ex2-1.htm", "category_name": "Agreement and Plan of Merger and Reorganization", "company_name": "Adamis Pharmaceuticals Corp", "created": "February 27th, 2023", "published": true, "pretty": null, "uri": "/contracts/eAwZU310eLv", "title": "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION between ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation, AARDVARK MERGER SUB, INC., a Delaware corporation and DMK PHARMACEUTICALS CORPORATION, a New Jersey corporation Dated as of February...", "group_id": "eAwZU310eLv", "group_samples": [{"label": "Agreement and Plan of Merger and Reorganization (Adamis Pharmaceuticals Corp)", "uri": "/contracts/jlSOykTrZS8", "published": true}, {"label": "Agreement and Plan of Merger and Reorganization (Adamis Pharmaceuticals Corp)", "uri": "/contracts/eAwZU310eLv", "published": true}], "group_size": 2, "tags": [{"name": "Agreement and Plan of Merger and Reorganization", "type": "category", "uri": "/contracts/tagged/agreement-and-plan-of-merger-and-reorganization"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS LOAN RELEASE AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of November 14, 2016 (the \u201cAgreement Date\u201d), by and among 4 HIMS, LLC, an Arkansas limited liability company (\u201c4 HIMS\u201d), TRIBUTE LABS, LLC, a Nevada limited liability company (\u201cTribute\u201d), U.S. COMPOUNDING, INC., an Arkansas corporation (\u201cUSC\u201d); EDDIE GLOVER, an individual; WILLIAM L. SPARKS, an individual; SAM GLOVER, an individual; RUSTY WOOTEN, an individual; STUART BURKE, an individual; and KRISTEN RIDDLE, an individual (collectively, the \u201cIndividual Guarantors\u201d); ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (\u201cAdamis\u201d); and BEAR STATE BANK, INC., a national banking association (\u201cBank\u201d).", "id": "13eIYTGrT9X", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713117001745/ex10-65.htm", "category_name": "Loan Release Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "March 30th, 2017", "published": true, "pretty": null, "uri": "/contracts/13eIYTGrT9X", "title": "LOAN RELEASE AGREEMENT", "group_id": "13eIYTGrT9X", "group_samples": [{"label": "Loan Release Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/13eIYTGrT9X", "published": true}], "group_size": 1, "tags": [{"name": "Loan Release Agreement", "type": "category", "uri": "/contracts/tagged/loan-release-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Arkansas", "type": "jurisdiction", "uri": "/contracts/tagged/arkansas-us"}]}, {"intro": "This Asset Purchase Agreement (the \u201cAgreement,\u201d which term shall include the Exhibits hereto) is hereby entered into by and between:", "id": "15rtXNvwwwR", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713121008161/ex2-1.htm", "category_name": "Asset Purchase Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "August 5th, 2021", "published": true, "pretty": null, "uri": "/contracts/15rtXNvwwwR", "title": "Asset Purchase Agreement", "group_id": "15rtXNvwwwR", "group_samples": [{"label": "Asset Purchase Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/15rtXNvwwwR", "published": true}], "group_size": 1, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Adamis Pharmaceuticals Corporation 2009 Equity Incentive Plan (the \u201cPlan\u201d).", "id": "1DndH8Rb9y4", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713117001745/ex10-4.htm", "category_name": "Restricted Stock Unit Award Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "March 30th, 2017", "published": true, "pretty": null, "uri": "/contracts/1DndH8Rb9y4", "title": "ADAMIS PHARMACEUTICALS CORPORATION RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND AWARD AGREEMENT (2009 EQUITY INCENTIVE PLAN)", "group_id": "1DndH8Rb9y4", "group_samples": [{"label": "Restricted Stock Unit Award Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/1DndH8Rb9y4", "published": true}], "group_size": 1, "tags": [{"name": "Restricted Stock Unit Award Agreement", "type": "category", "uri": "/contracts/tagged/restricted-stock-unit-award-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "", "id": "1J01Tz8NCXq", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713110000266/ex-10_1.htm", "category_name": "Termination of Merger Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "March 4th, 2010", "published": true, "pretty": null, "uri": "/contracts/1J01Tz8NCXq", "title": "LAJOLLA", "group_id": "1J01Tz8NCXq", "group_samples": [{"label": "Termination of Merger Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/1J01Tz8NCXq", "published": true}], "group_size": 1, "tags": [{"name": "Termination of Merger Agreement", "type": "category", "uri": "/contracts/tagged/termination-of-merger-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS FIRST AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this \"Agreement\") is made and entered into as of January 16, 2006 (the \u201cAgreement Date\u201d), by and between Cellegy Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 1800 Byberry Road, Building 13, Huntingdon Valley, PA, 19006-3525 USA (\"Cellegy\"), and Strakan International Limited, a company organized and existing under the laws of Bermuda with a branch office at Buckholm Mill, Galashiels, TD1 2HB, UK (\"Licensee\u201d\").", "id": "1Y3M7xDlXyT", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000114420406012628/v038451_ex10-31.htm", "category_name": "Exclusive License Agreement", "company_name": "Cellegy Pharmaceuticals Inc", "created": "March 31st, 2006", "published": true, "pretty": null, "uri": "/contracts/1Y3M7xDlXyT", "title": "First Amended and Restated Exclusive License Agreement For Tostrex\u00ae Between STRAKAN INTERNATIONAL LIMITED And Cellegy Pharmaceuticals, Inc. Confidential", "group_id": "1Y3M7xDlXyT", "group_samples": [{"label": "Exclusive License Agreement (Cellegy Pharmaceuticals Inc)", "uri": "/contracts/1Y3M7xDlXyT", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive License Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-license-agreement"}, {"name": "Cellegy Pharmaceuticals Inc", "type": "company", "uri": "/company/887247/cellegy-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Pennsylvania", "type": "jurisdiction", "uri": "/contracts/tagged/pennsylvania-us"}]}, {"intro": "This Agreement is dated as of the 26th day of June, 2013 among Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cCompany\u201d), the subscribers listed on Schedule 1 hereto (\u201cSubscribers\u201d), and Grushko & Mittman, P.C. (the \u201cEscrow Agent\u201d):", "id": "1g0Z2yeJQ8W", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713113002429/ex10-3.htm", "category_name": "Escrow Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 2nd, 2013", "published": true, "pretty": null, "uri": "/contracts/1g0Z2yeJQ8W", "title": "ESCROW AGREEMENT", "group_id": "1g0Z2yeJQ8W", "group_samples": [{"label": "Escrow Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/1g0Z2yeJQ8W", "published": true}], "group_size": 1, "tags": [{"name": "Escrow Agreement", "type": "category", "uri": "/contracts/tagged/escrow-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS LOAN AMENDMENT, FORBEARANCE AND ASSUMPTION AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of April _____, 2016 (the \u201cAgreement Date\u201d), by and among 4 HIMS, LLC, an Arkansas limited liability company (\u201c4 HIMS\u201d), Tribute Labs, LLC, a Nevada limited liability company (\u201cTribute\u201d), US Compounding, Inc., an Arkansas corporation (\u201cUSC\u201d) (4 HIMS, Tribute and USC are collectively hereinafter referred to as the \u201cInitial Loan Parties\u201d); EDDIE GLOVER, an individual, and WILLIAM L. SPARKS, an individual; and KRISTEN RIDDLE, an individual (collectively, the \u201cIndividual Guarantors\u201d); Adamis Pharmaceuticals Corporation, a Delaware corporation (\u201cAdamis\u201d); and Bear State Bank, INC., a national banking association (\u201cBank\u201d).", "id": "2YPrO13gHzf", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713116006612/ex10-5.htm", "category_name": "Loan Amendment, Forbearance and Assumption Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "August 15th, 2016", "published": true, "pretty": null, "uri": "/contracts/2YPrO13gHzf", "title": "LOAN AMENDMENT, FORBEARANCE AND ASSUMPTION AGREEMENT", "group_id": "2YPrO13gHzf", "group_samples": [{"label": "Loan Amendment, Forbearance and Assumption Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/2YPrO13gHzf", "published": true}], "group_size": 1, "tags": [{"name": "Loan Amendment, Forbearance and Assumption Agreement", "type": "category", "uri": "/contracts/tagged/loan-amendment-forbearance-and-assumption-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Arkansas", "type": "jurisdiction", "uri": "/contracts/tagged/arkansas-us"}]}, {"intro": "FOR VALUE RECEIVED, US COMPOUNDING, INC., an Arkansas corporation (\u201cUSC\u201d), and ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (\u201cAdamis\u201d and together with USC, the \u201cMaker\u201d), jointly, severally, unconditionally and irrevocably promise to pay to the order of ARVEST BANK, an Arkansas state bank, as successor in interest to BEAR STATE BANK, N.A., whose mailing address is 2200 W. Pleasant Grove Road, Rogers, Arkansas 72758, its successors and assigns (\u201cBank\u201d), or to the order of any subsequent holder hereof, in lawful money of the United States of America, the principal sum of Two Million Ninety Two Thousand One Hundred Twelve and No/100 United States Dollars ($2,092,112.00), or so much as may be advanced hereunder, together with interest on the unpaid principal balance (calculated on the basis of a hypothetical year of three hundred sixty (360) days, but multiplied by the actual number of days in the interest calculation period), from the date hereof at a variable rate which sha", "id": "2qCURchEoRV", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713120008322/ex10-2.htm", "category_name": "Promissory Note", "company_name": "Adamis Pharmaceuticals Corp", "created": "September 15th, 2020", "published": true, "pretty": null, "uri": "/contracts/2qCURchEoRV", "title": "AUGUST 2020 AMENDED AND RESTATED PROMISSORY NOTE Loan No. 5500000152", "group_id": "2qCURchEoRV", "group_samples": [{"label": "Promissory Note (Adamis Pharmaceuticals Corp)", "uri": "/contracts/2qCURchEoRV", "published": true}], "group_size": 1, "tags": [{"name": "Promissory Note", "type": "category", "uri": "/contracts/tagged/promissory-note"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS INTERCREDITOR AGREEMENT (this \"Agreement\") dated as of June 26, 2013, among the parties whose names are subscribed on the signature page hereto as Junior Lenders (collectively, the \u201cJunior Lenders\u201d), the parties identified on Schedule A-1 hereto (collectively the \u201cSenior Lenders\u201d), and Adamis Pharmaceuticals Corporation, a Delaware corporation (the \u201cBorrower\u201d).", "id": "2sbwHv8qE6T", "source_url": "https://www.sec.gov/Archives/edgar/data/887247/000138713113002429/ex10-5.htm", "category_name": "Intercreditor Agreement", "company_name": "Adamis Pharmaceuticals Corp", "created": "July 2nd, 2013", "published": true, "pretty": null, "uri": "/contracts/2sbwHv8qE6T", "title": "INTERCREDITOR AGREEMENT", "group_id": "2sbwHv8qE6T", "group_samples": [{"label": "Intercreditor Agreement (Adamis Pharmaceuticals Corp)", "uri": "/contracts/2sbwHv8qE6T", "published": true}], "group_size": 1, "tags": [{"name": "Intercreditor Agreement", "type": "category", "uri": "/contracts/tagged/intercreditor-agreement"}, {"name": "Adamis Pharmaceuticals Corp", "type": "company", "uri": "/company/887247/adamis-pharmaceuticals-corp"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLMnNid0h2OHFFNlQYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAwKGQoIZ3JvdXBfaWQSDRoLNlFabXQxWmhvdXQYACAB"}}